Clinical Trial

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucoma and Fuchs endothelial corneal dystrophy after cataract surgery. The main question it aims to answer is: do topical ROCK inhibitors decrease the loss of corneal endothelial cells after cataract surgery? Researchers will compare topical ROCK inhibitor to a placebo (a look-alike substance that contains no drug) Participants will: Take topical ROCK inhibitor or a placebo every day for 4 weeks after cataract surgery and visit the clinic for checkups and tests.
Trial Details
NCT Number NCT06969586
Lead Sponsor University Hospital Dubrava
Conditions Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma
Enrollment 50 participants
Start Date 2025-04-01
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-14